Gilead’s ESG Awards Are Worthless. What About Drug Prices?

GILEAD logo on building

By John Arcano Diversifying your workforce represents a worthy goal. Yet, corporate social responsibility awards distract from what really matters to pharmaceutical company customers: whether or not they can afford life-saving medicines. Corporate “Environmental and Social Governance” (ESG) performance ratings are less than worthless. Yet, companies cannot wait to show off when they make the cut. Giddy communications shops rush … Read More

Federal court rejects drugmaker’s efforts to end lawsuit claiming they delayed more effective HIV treatment for more expensive, less effective drug

ELURA NANOS | Jan 15th, 2024 A California appeals court has ruled that a pharmaceutical company can be held legally responsible for slow-walking the sale of an effective AIDS drug, because its decision may have been made solely to maximize its own profits. In a first-of-its-kind ruling, the California First District Court of Appeals in San Francisco ruled Tuesday that pharma giant Gilead Life Sciences can … Read More

‘Responsible Investors: Dump Gilead’ Says AHF Ad

$1200 pill encapsulates drugmaker’s incessant greed as Gilead Sciences engages in patent manipulation and obscene price hikes SAN FRANCISCO (October 7, 2023) – AIDS Healthcare Foundation (AHF) has launched a new advertisement in its ongoing campaign against Gilead Sciences’ incessant greed. The full-page, full-color newspaper ad debuts this Sunday, October 8th in the San Francisco Chronicle and New Jersey’s Daily Record and will run weekly through … Read More

HIV drugmaker will pay $246 million to settle suit over generic meds delay

Gilead Sciences will pay $246.75 million to customers who purchased the drugs Truvada or Atriplia, or any of the two drugs’ generic versions, during a period of about five years. MICHAEL GENNARO / September 25, 2023 SAN FRANCISCO (CN) — A federal judge on Monday gave preliminary approval to a $246.75 million class action settlement between Gilead Sciences and KPH Health … Read More

How a Drugmaker Profited by Slow-Walking a Promising H.I.V. Therapy

Gilead delayed a new version of a drug, allowing it to extend the patent life of a blockbuster line of medications, internal documents show. David Swisher is among the people suing Gilead. He took the company’s H.I.V. drug Truvada for 12 years and developed kidney disease and osteoporosis. By Rebecca Robbins and Sheryl Gay Stolberg Published July 22, 2023Updated July 23, 2023 In 2004, Gilead … Read More

Gilead must stand trial over defective HIV drug claims

The plaintiffs say they suffered unnecessary kidney and bone damage from taking one of Gilead’s drugs, which could have swapped out an ingredient for a safer alternative. NATALIE HANSON / September 29, 2023 OAKLAND, Calif. (CN) — The biopharmaceutical drug giant Gilead Sciences Inc. must face claims in a federal lawsuit that the company sold defective drugs to people living with … Read More

AHF Protest: Gilead Destroys Rx Safety Net for its Own Profit

Gilead Protest, Thursday, May 5th, 12:00 pm Foster City, CA In March, Gilead imposed conditions illegally restricting access on 340B drug pricing to its branded hepatitis C treatments when covered entities use outside contract pharmacies.  Gilead has the ignominious distinction of being the 15th manufacturer to place similar unlawful restrictions on certain 340B contract pharmacy programs SAN FRANCISCO (May 3, … Read More

AHF Protests Gilead over Drug Pricing @ Morgan Stanley Conf. in NYC

In less than two years, Gilead has more than doubled the cost of its HIV medication, Descovy, for the lifesaving 340B program from $445.11 in Q2, 2020 to $987.55 in Q2, 2022 AHF will host a protest Tuesday, Sept. 13th targeting Gilead Sciences—”Greediad”—and its investors over its AIDS drug pricing during the annual Morgan Stanley Global Healthcare Conference in New York … Read More

AHF Advocates to Hammer Gilead with Weeklong Protests

Twice-daily Protests at Company’s Foster City HQ—Oct. 24-Oct. 28 Advocates to protest Gilead’s drug pricing and policies, including illegal restrictions the company placed on access to 340B drug pricing for its branded hepatitis C treatments when covered entities use outside contract pharmacies SAN FRANCISCO (October 23, 2022) Starting Monday, October 24th, as many as 55 advocates and mobilizers affiliated with … Read More